GM 2296

Drug Profile

GM 2296

Latest Information Update: 07 Feb 2001

Price : $50

At a glance

  • Originator Glycomed
  • Developer Genentech; Glycomed
  • Class Anti-inflammatories; Anti-ischaemics
  • Mechanism of Action Selectin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 07 Feb 2001 Discontinued-Preclinical for Inflammation in USA (Unknown route)
  • 24 Sep 1998 Sankyo is a licensee in Japan for GM 2296
  • 24 Sep 1998 Profile reviewed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top